http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2441023-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86de7d9f2e6454d7c2f6aeaf3b9541b6 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate | 2010-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9476298fe8fa312832665179e9181cf6 |
| publicationDate | 2012-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2441023-C1 |
| titleOfInvention | Drug for multiple sclerosis and method for treating multiple sclerosis |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to a drug for multiple sclerosis which is presented in the form of a pharmaceutical composition and contains an activated potentiating form of human gamma-interferon (IFN-γ) antibodies and an activated potentiating form of brain-specific protein S-100 antibodies as an additive intensifying component. Using the drug in a method for treating multiple sclerosis involves in introduction of the activated potentiating form of human gamma-interferon (IFN-γ) in combination with the intensifying component in the form of the activated potentiating form of very-low-dose affinity purified brain-specific protein S-100 antibodies. n EFFECT: use of the inventions allows higher clinical effectiveness in multiple sclerosis. n 9 cl, 1 ex |
| priorityDate | 2010-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.